Posts by Ryan Worthen

Ryan is a Senior Research Analyst at PharmSource. He holds a BS degree in biology, with a minor in chemistry and a BA degree in Spanish, from the University of North Carolina at Chapel Hill. Prior to joining PharmSource, Ryan worked as a Research Technician in the Neuroscience Center of the UNC Chapel Hill School of Medicine, and has been a named author on research publications.

Prospect Profile: Vitae Pharmaceuticals

Prospect Profile highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Vitae Pharmaceuticals is a U.S. public pharmaceutical company that develops small molecule compounds for the treatment of diabetes, Alzheimer’s disease, autoimmune disorders, atopic dermatitis, and acute coronary syndrome. As […]

Learn more

Prospect Profile: Celladon Corporation

Prospect Profile highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Celladon Corporation is a U.S. public pharmaceutical company that develops treatments for cardiovascular diseases through the application of scientific discoveries in molecular cardiology. As reported in the August 21, […]

Learn more

Prospect Profile: Immune Design Corp.

Prospect Profile highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Immune Design Corp. is a U.S. public pharmaceutical company that develops therapeutic vaccines for the treatment of infectious and malignant disease. As reported in the July 31, 2014 issue […]

Learn more

Prospect Profile: Raptor Pharmaceutical Corp.

Prospect Profile highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Raptor Pharmaceutical Corp. is a U.S. public pharmaceutical company that develops treatments for metabolic disorders. As reported in the July 3, 2014 issue of the PharmSource Lead Sheet, Raptor […]

Learn more

Prospect Profile: Alder Biopharmaceuticals, Inc.

Prospect Profile highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Alder Biopharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops and manufactures novel antibody therapeutics to treat autoimmune and inflammatory diseases. As reported in the May 8, 2014 […]

Learn more

Prospect Profile: Adamas Pharmaceuticals, Inc.

Prospect Profile highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Adamas Pharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops and commercializes highly engineered, controlled-release combination products with an initial focus on treatments for infectious disease and CNS […]

Learn more

Prospect Profile: Achaogen, Inc.

Prospect Profile highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Achaogen, Inc. is a U.S. public pharmaceutical company that discovers and develops new antibiotics for the treatment of serious, multidrug-resistant Gram-negative bacterial infections. As reported in the March 20, […]

Learn more